---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-068503"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:21:07.161555+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ArriVent BioPharma enters ADC collaboration with Alphamab; milestones up to $615.5M

## Summary
- Collaboration to discover, develop, and commercialize novel antibody drug conjugates (ADCs) for cancers.
- Total upfront and milestone payments to Alphamab up to $615.5 million plus tiered sales royalties.
- ArriVent gains exclusive rights to develop and commercialize ADCs outside greater China; Alphamab retains greater China rights.
- Deal leverages Alphamab's proprietary linker-payload platform and glycan-conjugation technology.
- ArriVent CEO Bing Yao cites potential to add multiple innovative ADC programs to pipeline.

## SEC filing metadata
- accession: 0001104659-24-068503
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465924068503/0001104659-24-068503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465924068503/tm2416477d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-068503
- JSON: https://secwatch.observer/filing/0001104659-24-068503.json
- Plain text: https://secwatch.observer/filing/0001104659-24-068503.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.